Oct 30, 2026 · Sports, Health & Nutrition Daily Digest

A same-day digest of exercise, wellness, and nutrition science for October 30, 2026, with summaries, links, and commentary.

I. Nutrition & Diet

1. Menopause / WHI secondary analysis: A low-fat, produce-and-grain-rich pattern did not cut dementia deaths in postmenopausal women (Nutrition)

Summary:

PsyPost reported on October 30 that Rowan T. Chlebowski (Lundquist Institute) and colleagues published a long-term secondary analysis of the Women’s Health Initiative Dietary Modification randomized trial in Menopause. The parent trial enrolled 48,835 U.S. postmenopausal women aged 50–79 with baseline fat ≥32% of energy; 40% were assigned to a dietitian-guided low-fat pattern (about 20% of energy from fat plus more fruits, vegetables, and grains) and 60% to usual diet. Intensive intervention lasted a median 8.5 years, with about 20 years of cumulative follow-up. Among 1,386 dementia-related deaths, the intervention did not change overall dementia mortality (HR 0.94, 95% CI 0.85–1.05), Alzheimer mortality (HR 1.00), or non-Alzheimer dementia mortality (HR 0.90). Younger enrollees showed a trend toward lower dementia mortality (P-trend 0.03); women aged 70–79 did not. Outcomes used dementia as cause of death, not incidence; subgroups need caution.

Links:

• Menopause — WHI low-fat dietary pattern and dementia mortality (DOI)
• PsyPost — October 30 report on low-fat diets and dementia deaths in older women

Commentary:

Do not treat “cut fat, add produce” as a proven prescription against dementia death—it may still help weight, blood pressure, and diabetes risk, while brain health needs earlier, broader attention to sleep, blood pressure, and cognitive engagement.

2. Food & Function crossover RCT: 60 g/day unsalted skin-roasted peanuts for 16 weeks shifted insulin-related brain blood-flow responses in older adults (Nutrition)

Summary:

Maastricht University Medical Center investigators ran a single-blind randomized crossover trial (NCT05724654) in 31 older adults (67±4 years): 16 weeks of 60 g/day unsalted skin-roasted peanuts versus a no-peanut control, separated by an 8-week washout. Euronews and related outlets covered the Food & Function paper on October 30. Brain insulin responsiveness was indexed by arterial-spin-labeling MRI cerebral blood flow (CBF) after intranasal insulin. One right-hemisphere cluster spanning memory-related regions (hippocampus, parahippocampal gyrus, lingual gyrus, and nearby structures) showed a lower CBF response after peanuts versus control (mean difference −5.4±5.4 mL/100 g tissue/min; P=0.044), which authors interpret as a potentially favorable regional insulin response. Intrahepatic lipid and circulating glucose, lipid, and low-grade inflammation markers were unchanged. Limits include small sample, single-blind design, and industry funding context; this is not a dementia-prevention claim.

Links:

• Food & Function — Daily unsalted skin-roasted peanuts and brain insulin responsiveness
• Euronews — October 30 report on daily peanuts and brain function

Commentary:

If you tolerate peanuts, swap a small unsalted handful for sugary snacks—this is a small mechanistic signal, not a “peanuts prevent dementia” prescription.

3. Clinical Gastroenterology and Hepatology cohort (~200,000): Eating after dinner or bedtime linked to higher MASLD and cirrhosis risk (Nutrition)

Summary:

Robert M. Wilechansky (Oregon Health & Science University) and colleagues pooled participants without baseline liver disease from the Nurses’ Health Study, NHS II, and Health Professionals Follow-up Study (about 199,155 people; median follow-up ~16 years). Gastroenterology Advisor, OHSU News, and other outlets recently covered the Clinical Gastroenterology and Hepatology paper. They documented 4,492 incident MASLD events and 315 incident cirrhosis events. After multivariable adjustment, late-night eating (after dinner or after bedtime) was associated with cirrhosis aHR 1.28 and MASLD aHR 1.36; skipping breakfast and irregular meal frequency were no longer significant after full adjustment. Adjusting for night-shift work strengthened the cirrhosis association (aHR 1.49). Observational design, coarse self-reported meal timing, and incomplete sleep-phase measurement preclude causal claims.

Links:

• Clinical Gastroenterology and Hepatology — Late-night eating, MASLD, and cirrhosis (DOI)
• OHSU News — Late-night eating and liver disease risk

Commentary:

When feasible, finish calories several hours before bed—this is association evidence; weight, alcohol, and metabolic risks still come first.

4. Obesity 3-year cohort: In severe obesity, surgery and structured diet cut energy intake similarly in year 1; only surgery kept intake down later (Nutrition)

Summary:

Medscape covered on October 30 a prospective nonrandomized Obesity cohort of 57 adults with severe obesity (median age 52; median BMI 40; 72% women) who underwent LAGB (n=11), sleeve gastrectomy (n=21), RYGB (n=7), or a structured diet program (n=18) and were followed for 3 years. In year 1, reported energy intake fell across groups (−1322 kJ per visit) with no significant between-group differences. Between 12 and 24 months, intake rose in the diet group (~+3089 kJ per visit) while surgical groups stayed comparatively stable. At 3 years, weight remained about 25.1% (SG), 26.4% (RYGB), and 16.9% (LAGB) below baseline; diet participants were not weighed at year 3. Premeal appetite fell most durably after SG. Nonrandomized assignment, self-reported diet, and small cells limit inference.

Links:

• Obesity — Long-term energy intake and appetite after bariatric surgery vs diet (DOI)
• Medscape — October 30 report on surgery vs diet for sustained lower energy intake

Commentary:

If severe obesity is managed without surgery, plan intensive dietary support after year one—do not assume early calorie cuts will hold on their own.

II. Exercise & Training Science

5. European Review of Aging and Physical Activity systematic review: Low-load blood-flow-restriction resistance can build lower-limb strength and muscle area in healthy older adults (Training)

Summary:

Matic Jelen, Manca Opara Zupančič, and Nejc Šarabon reviewed RCTs through May 2026 and included six trials (197 healthy adults, mean age ≥60) comparing blood-flow-restriction resistance exercise (BFR-RE) with low- or high-intensity resistance training or no exercise. Heterogeneous outcomes forced a descriptive synthesis. All studies reported strength gains: knee-extension 1RM rose about 15.6%–26.1%, and horizontal leg-press 1RM about 33.4%–54%; quadriceps cross-sectional area rose about 3.23–4.2 cm², with effects generally comparable to traditional high-intensity training. Functional data were sparse; no included study was overall low risk of bias; BFR arms had only 8–20 participants; absence of reported adverse events is not proof of safety. Authors frame BFR-RE as an option when heavy loads are poorly tolerated, with limited certainty.

Links:

• European Review of Aging and Physical Activity — BFR resistance exercise in older adults
• Bioengineer — Low-load BFR training and older adults’ leg strength

Commentary:

If joints or clinicians limit heavy loading, ask a trained professional about protocolized low-load BFR—do not DIY cuff pressures, and do not treat this as strong fall-prevention evidence.

6. European Review of Aging and Physical Activity RCT: In older women, three weekly elastic-band sessions beat two for grip strength and HDL (Training)

Summary:

A single-blind RCT across three geriatric centers in Vojvodina, Serbia, randomized 82 women (75.1±8.6 years) to two or three weekly low-load elastic-band sessions (n=41 each) for 12 weeks. Per-session dose was matched (2 sets of 12–15 reps at 40%–50% 1RM; OMNI 4–5); adherence exceeded 90%. Both groups improved chair stand, arm curl, flexibility, and grip measures; between-group gains favored three sessions for handgrip (+28% vs +7%) and HDL (~+9% vs +1%). Total and LDL cholesterol fell similarly; fasting glucose and triglycerides did not change significantly. Authors note the thrice-weekly arm completed 50% more weekly volume, so frequency cannot be separated from volume; there was no non-training control, and diet/activity were not standardized.

Links:

• European Review of Aging and Physical Activity — Two vs three weekly elastic-band sessions RCT
• Bioengineer — Three weekly elastic-band sessions, grip strength, and HDL

Commentary:

Aim for three short full-body band sessions weekly when you can; twice weekly still helps—extra grip and HDL upside may simply track total weekly dose.

7. Neuroscience mouse study: Overtraining kept hippocampal dopamine elevated during rest, underscoring recovery for brain chemical balance (Training)

Summary:

Agência FAPESP reported on October 30 that Alisson Luiz da Rocha, Adelino Sanchez Ramos da Silva (University of São Paulo), and colleagues published in Neuroscience. Mice completed either an acute treadmill-to-exhaustion test or an 8-week progressive overtraining protocol ending with two daily sessions only ~4 hours apart. In the chronic group, hippocampal dopamine and tyrosine hydroxylase remained elevated for 48 hours into the rest phase after a performance test; the acute group mainly showed a short post-run dopamine rise. Serotonin did not differ meaningfully between groups. Sleep, anxiety, and alertness were not measured. Authors say a similar human mechanism—if confirmed—might help explain overtraining-related insomnia and anxiety, but this remains animal evidence.

Links:

• Neuroscience — Excessive training and hippocampal dopamine homeostasis in mice
• Agência FAPESP — October 30 report on overtraining and brain chemical regulation

Commentary:

Pair hard sessions with scheduled rest days and sleep windows—this paper does not diagnose or treat humans, but it reinforces recovery as part of the training plan.

III. Sleep & Mental Health

8. Sleepio After Cancer phase 3 RCT: Digital CBT-I improved insomnia in women with cancer, with gains in fatigue, mood, and hot flashes (Sleep)

Summary:

Medscape (October 30) and Healio covered the open-label Sleepio After Cancer randomized trial (NCT05816460) presented at ESMO: 308 women with current or prior cancer and clinical insomnia (median age 52; ~61% breast, ~29% gynecologic) were assigned to digital CBT-I (Sleepio, six weekly sessions; n=156) or sleep-hygiene education (n=152), both plus usual care. At 24 weeks, SCI improved more with digital CBT-I (adjusted mean difference 6.36; P<.001; Cohen d≈0.99). Intention-to-treat insomnia remission was 27% vs 12% (NNT≈7); among completers of assessment, 62% vs 19% (NNT≈3). Fatigue, depression, anxiety, and hot-flash interference also improved moderately. Only about 40% assigned to CBT-I finished all six sessions, and 24-week assessment completion was about 44% vs 34%. Findings are primarily conference-reported pending full peer-reviewed publication.

Links:

• Medscape — October 30 report on digital CBT for insomnia in women with cancer
• Healio — Sleepio digital CBT-I and cancer-related insomnia
• ClinicalTrials.gov — NCT05816460 Sleepio After Cancer

Commentary:

For cancer-related insomnia, ask about guideline-first CBT-I (including digital options)—sleep-hygiene tips alone are a weak default.

9. Eating and Weight Disorders cross-section: In medical students, depression and somatization partly mediated night-eating symptoms and poor sleep (Sleep)

Summary:

Bioengineer reported on October 30 a questionnaire study of 460 preclinical medical students published in Eating and Weight Disorders. About 70% had poor sleep (PSQI>5); those with poor sleep scored higher on NEQ, PHQ-9, PHQ-15, and GAD-7. PSQI correlated with NEQ (r=0.498), PHQ-9 (r=0.493), and PHQ-15 (r=0.422). Bootstrap mediation (5,000 resamples) found significant indirect paths through depression (PHQ-9) and somatization (PHQ-15), but not panic or generalized anxiety. Cross-sectional design in a single young student cohort cannot establish causation or temporal order.

Links:

• Eating and Weight Disorders — Night eating, depression/somatization, and sleep quality (DOI)
• Bioengineer — October 30 report on night eating and sleep mediation pathways

Commentary:

If night eating and insomnia travel together, screen mood and somatic distress—not only the midnight snack list—and seek clinical help when needed.

IV. Public Health & Evidence Clarification

10. FDA: Multiple “natural” weight-loss and pain products found to contain undeclared prescription drugs (Evidence)

Summary:

The U.S. Food and Drug Administration recently warned consumers after lab testing: Demograss Premier (marketed for weight loss; notice ~October 27) contained undeclared phenolphthalein (not an approved U.S. drug ingredient; studies suggest possible cancer risk); Ort-Flx (marketed for pain, arthritis, and allergies; ~October 28) contained undeclared diclofenac, dexamethasone, and methocarbamol; Ultra Bon (marketed for arthritis/osteoporosis; ~October 23) contained undeclared diclofenac. Hidden NSAIDs and corticosteroids can raise cardiovascular, GI-bleeding, and withdrawal risks. Products are often sold online as supplements or “all natural”; FDA cannot test every marketplace item.

Links:

• FDA — Demograss Premier may contain undeclared phenolphthalein
• FDA — Ort-Flx may contain undeclared drug ingredients
• FDA — Ultra Bon may contain undeclared diclofenac

Commentary:

Treat “miracle herb” weight-loss or pain pills that work like drugs as suspect—buy traceable brands and tell clinicians everything you take.

11. Frontiers in Physiology double-blind RCT: 21 days of vitamin D₃ raised 25(OH)D and shifted some inflammatory markers but did not boost anaerobic performance (Evidence)

Summary:

Thirty physically active men were randomized to vitamin D₃ 10,000 IU/day or placebo for 21 days (27 analyzed) with blood draws around a 2×Wingate Anaerobic Test. Resting 25(OH)D rose about 55.7% in the supplement arm. Wingate outcomes showed no differential performance benefit versus placebo. At rest, the vitamin D₃ group had lower IL-1β and IL-6 and higher IL-10; after exercise, IL-1β responses were attenuated and IL-10 higher, while the post-exercise IL-6 time course did not differ between groups. Functional recovery was not measured; short high-dose protocols should not be self-prescribed.

Links:

• Frontiers in Physiology — 21-day vitamin D₃, anaerobic performance, and exercise inflammation

Commentary:

Test before you mega-dose—three weeks of vitamin D is not a Wingate booster, and cytokine shifts are not the same as faster recovery.

Today's Summary

• WHI long-term data cool “diet-as-dementia-vaccine” claims, while a small peanut trial shows diet can still nudge memory-related brain insulin responses.
• Meal timing and severe-obesity care both matter: late eating tracks higher liver-disease risk, and surgery holds calorie restraint better than structured diet after year one.
• Older-adult training stays practical: BFR and thrice-weekly bands offer low-load paths; mouse overtraining data re-centers recovery.
• Sleep care and supplement safety diverge: digital CBT-I strengthens options for cancer-related insomnia, while “natural” weight-loss/pain products keep hiding drugs.

Daily Framing:

Today was an evidence-calibration day in sports/health/nutrition—large trials dampened diet-as-dementia-cure narratives, while mechanism and dosing studies pulled attention back to meal timing, accessible strength work, and real insomnia treatment.

This digest is compiled from real-time search results and is for reference only.